Endpoint

Triglycerides

An ester formed from glycerol and three fatty acid groups.

Definition from MeSH (D014280), National Library of Medicine, read 2026-09-23. NLM revises MeSH; this copy may not reflect its current record.

CAT:outcome/serum-triglyceridesreported in mg/dL41 findings from 24 compounds

Open in the graph

What moved it

How to read these marks

41 findings · 24 compounds · 17 null · by evidence strength

Compound	Direction	Findings	Strongest evidence
resveratrol	no effect 2 · down 2	4	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
berberine	down	3	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
pravastatin	down 2 · no effect 1	3	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
(R)-carnitine	no effect	2	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
crocin-1	down 1 · no effect 1	2	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
lipoic acid	down 1 · no effect 1	2	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
empagliflozin	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Lactiplantibacillus plantarum	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
nicotinamide	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
NMN zwitterion	no effect	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
piperine	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
sulforaphane	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
taurine	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
Zn(2+)	down	1	Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.
curcumin	no effect 1 · down 4	5	Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.
coenzyme Q10	no effect	3	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
magnesium(2+)	no effect	2	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
Camellia sinensis	no effect	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
naringenin	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
quercetin	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
α-tocopherol	down	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.
aspartame	up	1	Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.
L-isoleucine	down	1	Evidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.

Reported to move it

24 findings

Zn(2+) — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“After analyzing the results of 14 studies with 17 effect sizes, a significant reduction in serum concentrations of TG was observed following zinc supplementation (WMD: −13.08; 95% CI: −21.83, −4.34; P = 0.003).”
Quoted verbatim from The Effect of Zinc Supplementation on Lipid Profiles in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials..
Study

meta-analysis
Population

Adults with type 2 diabetes mellitus; 14 randomised trials, zinc supplement versus placebo or no zinc, some trials with a co-supplement given identically in both arms
Effect -13.08 mean difference, 95% CI -21.83 to -4.34
The Effect of Zinc Supplementation on Lipid Profiles in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Dose-Response Meta-Analysis of Randomized Clinical Trials.2023PMID:37604307Permalink
pravastatin — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1
“The average of differences for triglycerides until 5 years was significantly reduced with 10 mg daily of pravastatin(P=0.023).”
Quoted verbatim from Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke)..
Study

RCT
Dose

10 mg daily
Population

Japanese patients aged 45-80 with noncardioembolic ischemic stroke and serum total cholesterol 180-240 mg/dL without statins, pravastatin 10 mg daily versus no statin (open-label); J-STARS Echo substudy
Long-Term Effect of Pravastatin on Carotid Intima-Media Complex Thickness: The J-STARS Echo Study (Japan Statin Treatment Against Recurrent Stroke).2018PMID:29191850Permalink
berberine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2
“BBR exhibited greater decreases in body weight, BMI, waist, HFC, serum cholesterol and triglycerides compared with LSI alone (Additional file 1: Table S1), which demonstrates a clearly significant benefit of BBR on metabolism.”
Quoted verbatim from Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease..
Study

RCT
Duration

4 months
Dose

berberine 0.5 g three times daily, 30 min before meals
Population

Adults with nonalcoholic fatty liver disease and impaired glucose regulation or type 2 diabetes; lifestyle intervention (diet and exercise) given to both arms, berberine added in one; 80-patient lipidomics subsample (41 berberine, 39 lifestyle alone)
Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease.2016PMID:27629750Permalink
berberine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2
“BBR significantly reduced TG compared to placebo (WMD = −23.70 mg/dl; 95% CI, −30.16 to −17.25; P < 0.001).”
Quoted verbatim from The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis..
Study

meta-analysis
Population

Adults in randomised controlled trials of berberine (type 2 diabetes, dyslipidaemia, metabolic syndrome, fatty liver disease, PCOS and other populations)
Effect -23.7 mean difference, 95% CI -30.16 to -17.25
The effects of berberine supplementation on cardiovascular risk factors in adults: A systematic review and dose-response meta-analysis.2022PMID:36313096Permalink
nicotinamide — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Mean triglyceride concentrations decreased over time in both treatment groups, although the decrease was more pronounced in the NAMR group, with significant differences between the treatment groups at weeks 12, 24 and 52.”
Quoted verbatim from Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial..
Study

RCT
Duration

12 months
Dose

modified-release nicotinamide 250-1500 mg/day (one to six 250 mg capsules once daily before bed)
Population

Adults on maintenance haemodialysis with hyperphosphataemia, modified-release nicotinamide versus placebo, both arms on their individual phosphate binders
Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial.2023PMID:35751625Industry fundedPermalink
piperine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Serum concentrations of cholesterol, LDL, and TG were significantly reduced after the timeline of intervention in participants of case arm in comparison to the participants of control arm (P value < 0.001, P value = 0.043, P value = 0.005, respectively).”
Quoted verbatim from The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial..
Study

RCT
Duration

3 months
Dose

5 mg piperine capsule daily
Population

Adults with ultrasound grade 2-3 NAFLD and raised ALT, Iran; blood drawn after 12 h overnight fast
The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial.2024PMID:38200253Permalink

Show the remaining 18

sulforaphane — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol.”
Quoted verbatim from Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

Patients with schizophrenia in pooled randomized controlled trials of sulforaphane versus control
Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials.2025PMID:41184790Permalink
crocin-1 — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“As listed in Table 2, comparison of the crocin and placebo groups for changes in variables (before- after) showed that mean serum TG levels decreased significantly in the crocin group compared with the increasing values in the placebo group (P-Value = 0.03).”
Quoted verbatim from Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial..
Study

RCT
Duration

3 months
Dose

15 mg crocin tablet daily
Population

Adults with type 2 diabetes and microalbuminuria on routine antidiabetic, antihypertensive and lipid-lowering care; crocin 15 mg/day versus placebo
Evaluation of therapeutic effects of crocin in attenuating the progression of diabetic nephropathy: a preliminary randomized triple-blind placebo-controlled trial.2022PMID:36209091Permalink
taurine — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“Compared to control groups, taurine supplementation demonstrated statistically significant reductions in SBP (weighted mean difference [WMD] = -3.999 mmHg, 95% confidence interval [CI] = -7.293 to -0.706, p = 0.017), DBP (WMD = -1.509 mmHg, 95% CI = -2.479 to -0.539, p = 0.002), FBG (WMD: -5.882 mg/dL, 95% CI: -10.747 to -1.018, p = 0.018), TG (WMD: -18.315 mg/dL, 95% CI: -25.628 to -11.002, p < 0.001), but not in HDL-C (WMD: 0.644 mg/dl, 95% CI: -0.244 to 1.532, p = 0.155).”
Quoted verbatim from Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

Pooled 25 RCTs (1024 participants) of taurine supplementation, 0.5 to 6 g/day, follow-up 5 to 365 days; MetS-related parameters
Effect -18.315 mean difference, 95% CI -25.628 to -11.002
Taurine reduces the risk for metabolic syndrome: a systematic review and meta-analysis of randomized controlled trials.2024PMID:38755142Permalink
lipoic acid — decreases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding
“At the end of the study, TG reduced significantly in the ALA group (P < 0.001) and the significant time to group interaction effect was observed (P = 0.03).”
Quoted verbatim from The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial..
Study

RCT
Duration

8 weeks
Dose

1200 mg ALA per day as two 600 mg capsules, one capsule twice daily 30 minutes before meals
Population

Patients with type 2 diabetes, aged 40 to 60 years, HbA1c below 7%, BMI 18.5 to 29.9, on stable metformin, sulfonylurea, statin, ACE inhibitor, ARB or low-dose aspirin therapy
The Beneficial Effects of Alpha Lipoic Acid Supplementation on Lp-PLA2 Mass and Its Distribution between HDL and apoB-Containing Lipoproteins in Type 2 Diabetic Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.2020PMID:32256955Permalink
berberine — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2
“Furthermore, the FBG, RBG and TG in BBR- and HGSD-treated mice were significantly lower than those in db/db mice, and the OGTT and ITT were significantly improved compared with those in the db/db group.”
Quoted verbatim from Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2β/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 β-cells..
Study

animal · not in humans
Dose

berberine 160 mg/kg daily for 4 weeks
Population

Male db/db mice treated with berberine alone versus saline-treated db/db mice; the sentence pools berberine-treated and Huang-Gui Solid Dispersion-treated mice
Amorphous solid dispersion of Berberine mitigates apoptosis via iPLA2β/Cardiolipin/Opa1 pathway in db/db mice and in Palmitate-treated MIN6 β-cells.2019PMID:31337982Permalink
quercetin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“The results showed that quercetin could effectively reduce TG levels (MD=-7.33, 95% CI=[-11.73, -2.93], P = 0.001), and the difference was statistically significant (Table 2).”
Quoted verbatim from Effects of quercetin on polycystic ovary syndrome in animal models: a systematic review and meta-analysis..
Study

animal · not in humans
Population

Meta-analysis of three studies in rodent models of polycystic ovary syndrome (DHEA- or letrozole-induced), quercetin versus model controls given no treatment or vehicle
Effect -7.33 mean difference, 95% CI -11.73 to -2.93
Effects of quercetin on polycystic ovary syndrome in animal models: a systematic review and meta-analysis.2024PMID:38637876Permalink
naringenin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“Naringenin consumption significantly reduced percentages of NAFLD grades (P < .001), as well as, serum levels of triglyceride (TG) (P < .001), total cholesterol (TC) (P = .01), and low-density lipoprotein (LDL) (P = .02) and increased serum level of high-density lipoprotein (HDL) (P = .02) compared with the control group.”
Quoted verbatim from Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial..
Study

RCT
Duration

4 weeks
Dose

100 mg capsules twice a day, before lunch and dinner
Population

44 overweight/obese patients with NAFLD, placebo-controlled
Does naringenin supplementation improve lipid profile, severity of hepatic steatosis and probability of liver fibrosis in overweight/obese patients with NAFLD? A randomised, double-blind, placebo-controlled, clinical trial.2021PMID:34516703Permalink
α-tocopherol — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“The pooled analysis of 12 RCTs showed that vitamin E in patients with MASLD significantly reduced TG (-12.74 mg/dL, 95% CI: [-22.78, -2.70], p = 0.013), whereas no significant change was observed in TC (-2.11 mg/dL, 95% CI: [-4.89, 0.67], p = 0.137) and LDL-C (-5.32 mg/dL, 95% CI: [-11.15, 0.51], p = 0.074), HDL-C levels (0.23 mg/dL, 95% CI: [-0.48, 0.94], p = 0.527), and BMI (0.36 kg/m2, 95% CI: [-0.86, 1.58], p = 0.563).”
Quoted verbatim from Efficacy of Vitamin E on Lipid Profile in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis..
Study

meta-analysis
Population

Adults with metabolic dysfunction-associated steatotic liver disease (MASLD); pooled analysis of 12 randomised controlled trials
Efficacy of Vitamin E on Lipid Profile in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.2026PMID:42092748Permalink
pravastatin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1
“Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%, total cholesterol by 16.1% to 23.3%,and triglycerides by 5.8% to 20.0%.”
Quoted verbatim from Pravastatin for lowering lipids..
Study

meta-analysis
Dose

10 mg/day to 80 mg/day
Population

Participants of any age, with and without evidence of cardiovascular disease, in randomized placebo-controlled trials of fixed pravastatin doses lasting three to 12 weeks; dose range 10 mg/day to 80 mg/day
Pravastatin for lowering lipids.2023PMID:37721222Permalink
resveratrol — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1
“Notably, serum insulin and triglycerides significantly decreased in the resveratrol group compared to placebo.”
Quoted verbatim from Supplementation with resveratrol modified gut microbiota improving insulin sensitivity and lipid metabolism in subjects with obesity and insulin resistance..
Study

RCT
Population

adults with obesity and insulin resistance
Supplementation with resveratrol modified gut microbiota improving insulin sensitivity and lipid metabolism in subjects with obesity and insulin resistance.2025PMID:41359054Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3
“This meta-analysis has shown that curcuminoid therapy significantly reduces plasma triglycerides and increases HDL-C levels.”
Quoted verbatim from Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials..
Study

meta-analysis
Population

adults in randomized controlled trials of curcuminoids
Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials.2019PMID:29185808Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3
“In addition, curcumin supplementation was significantly associated with triglyceride (SMD -1.21; 95 % CI, -1.78, -0.65; P<0.001) and total cholesterol reduction (SMD -0.73; 95 % CI, -1.32, -0.13; P= 0.01).”
Quoted verbatim from The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials..
Study

meta-analysis
Population

patients with metabolic syndrome (MetS) and related disorders
Effect -1.21 standardised mean difference, 95% CI -1.78 to -0.65
The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials.2018PMID:30156145Permalink
resveratrol — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×1
“Compared to the control group, RES intake significantly reduced systolic blood pressure (SBP), triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and improved ejection fraction (EF).”
Quoted verbatim from Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients..
Study

RCT
Duration

2 months
Population

patients undergoing coronary artery bypass grafting (CABG)
Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients.2025PMID:40676400Permalink
all-cis-docosa-4,7,10,13,16,19-hexaenoic acid — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“The results showed that both EPA and DHA were effective at lowering serum triglycerides (TG) levels.”
Quoted verbatim from Effects of dietary eicosapentaenoic acid and docosahexaenoic acid supplementation on metabolic syndrome: A systematic review and meta-analysis of data from 33 randomized controlled trials..
Study

meta-analysis
Population

Adults in 33 randomised controlled trials of pure eicosapentaenoic acid or pure docosahexaenoic acid preparations, pooled for features of the metabolic syndrome
Effects of dietary eicosapentaenoic acid and docosahexaenoic acid supplementation on metabolic syndrome: A systematic review and meta-analysis of data from 33 randomized controlled trials.2021PMID:34229258Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3
“There were also significant reductions in body mass index and serum levels of total cholesterol, low-density lipoprotein cholesterol, triglycerides, aspartate aminotransferase, alanine aminotransferase, glucose, and glycated hemoglobin compared with the placebo group.”
Quoted verbatim from Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial..
Study

RCT
Duration

8 weeks
Dose

amorphous dispersion curcumin formulation 500 mg/day (~70 mg curcumin) for 8 weeks
Population

adults with ultrasound-diagnosed nonalcoholic fatty liver disease
Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial.2016PMID:27270872Permalink
curcumin — decreases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×3
“As for the lipid profile parameters, serum triglycerides were significantly reduced following curcumin supplementation (p = 0.009).”
Quoted verbatim from Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial..
Study

crossover
Duration

4 weeks
Dose

1 g/day for 30 days
Population

obese individuals
Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial.2013PMID:22610853Permalink
aspartame — increases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“Also, ASP 2 and ASP 3 significantly increased the levels of total cholesterol, triglycerides and low-density lipoprotein cholesterol in the rats.”
Quoted verbatim from Effects of long-term administration of aspartame on biochemical indices, lipid profile and redox status of cellular system of male rats..
Study

animal · not in humans
Duration

2 months
Dose

35 and 70 mg/kg daily by oral gavage
Population

Male Wistar rats given aspartame 35 mg/kg (ASP 2) and 70 mg/kg (ASP 3) daily by oral gavage for 9 weeks versus distilled water; the 15 mg/kg dose is not covered by this sentence
Effects of long-term administration of aspartame on biochemical indices, lipid profile and redox status of cellular system of male rats.2016PMID:26247507Permalink
L-isoleucine — decreases
InsufficientEvidence strength: insufficient. Mechanistic inference, no evidence found, or evidence weakened below very limited.Finding
“The results showed that adding Leu, Ile and their combination in drinking water significantly decreased relative white adipose tissue (WAT) weight and serum triglycerides, low-density lipoprotein, free fatty acid, and insulin compared with the HFD control.”
Quoted verbatim from Leucine and isoleucine have similar effects on reducing lipid accumulation, improving insulin sensitivity and increasing the browning of WAT in high-fat diet-induced obese mice..
Study

animal · not in humans
Dose

isoleucine in drinking water
Population

already obese mice induced by high-fat diet; Ile given in drinking water, compared with HFD control (Ile arm separate from Leu and Leu+Ile arms)
Leucine and isoleucine have similar effects on reducing lipid accumulation, improving insulin sensitivity and increasing the browning of WAT in high-fat diet-induced obese mice.2020PMID:32104819Permalink

Measured, no effect detected

17 findings

resveratrol — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1
“The pooled effect estimate revealed no effect of resveratrol on triglycerides (MD = -8.25; 95% CI [-37.25, 20.74], P = 0.58).”
Quoted verbatim from Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials..
Study

meta-analysis
Participants

108
Population

Women with PCOS, pooled across 2 RCTs (n=108: 54 per arm).
Effect -8.25 mean difference, 95% CI -37.25 to 20.74
Efficacy of resveratrol in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized clinical trials.2023PMID:37333786Permalink
(R)-carnitine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1
“However, plasma HDL-C (WMD: 0.85 mg/dL, 95% CI: −2.34, 4.05, p = 0.601) and triglycerides (WMD: −2.42 mg/dL, 95% CI: −34.85, 30.01, p = 0.884) were not altered by L-carnitine.”
Quoted verbatim from Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials..
Study

meta-analysis
Dose

1 g 3 times per week to 4 g/day across included trials; 1 to 24 weeks
Population

Adults in 6 treatment arms of randomised trials (intravenous and oral L-carnitine pooled) reporting triglycerides, versus control
Effect -2.42 mean difference, 95% CI -34.85 to 30.01
Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials.2016PMID:26754058Industry fundedPermalink
(R)-carnitine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull resultreplicated ×1
“Similarly, FBS, TG, and HDLc with L-carnitine intervention presented no significant difference between the intervention and control groups.”
Quoted verbatim from L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials..
Study

meta-analysis
Dose

0.75 to 3 g/day across included RCTs, 8 to 24 weeks
Population

Adults in nine RCTs (diabetes mellitus, non-alcoholic steatohepatitis, knee osteoarthritis, hemodialysis); six RCTs contributed TG data; whole-population estimate
L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2020PMID:32932644Permalink
Lactiplantibacillus plantarum — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“Throughout the 24-week intervention, lipid profiles, including total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol, remained stable and within normal reference ranges in both the placebo and probiotic groups, with no statistically significant differences observed between groups (Table 3).”
Quoted verbatim from Safety of Lactiplantibacillus plantarum K014 in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial..
Study

RCT
Duration

6 months
Dose

one sachet daily, at least 1 x 10^9 CFU L. plantarum K014 with 2 g maltodextrin, for 24 weeks
Population

Healthy Malaysian adults aged 18 and over; whole 24-week intervention; maltodextrin placebo in the comparator arm
Safety of Lactiplantibacillus plantarum K014 in Healthy Adults: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial.2026PMID:42124006Permalink
NMN zwitterion — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“Regarding lipid indicators, NMN supplementation had no significant effect on HDL-C, LDL-C, total cholesterol, or triglycerides.”
Quoted verbatim from Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis..
Study

meta-analysis
Dose

250-2000 mg/day oral across included trials
Population

Adults in randomized controlled trials of oral NMN or NMN-related preparations (including MIB-626) against placebo or no-NMN controls; random-effects pooled analysis
Safety and Metabolism-Related Outcomes of Oral Nicotinamide Mononucleotide Supplementation in Adults: A Systematic Review and Meta-Analysis.2026PMID:42514320Permalink
empagliflozin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“In comparison with control group for non-alcoholic fatty liver disease, empagliflozin treatment shows no substantial impact on ALT (SMD=-0.09; 95% CI=-0.37 to 0.18; P=0.50; Figure 4), AST (SMD=-0.26; 95% CI=-0.53 to 0.02; P=0.07; Figure 5), LDL (SMD=-0.31; 95% CI=-0.74 to 0.11; P=0.15; Figure 6) or TG (SMD=-0.17; 95% CI=-0.54 to 0.19; P=0.35; Figure 7).”
Quoted verbatim from Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials..
Study

meta-analysis
Dose

10 mg daily
Population

Patients with non-alcoholic fatty liver disease, pooled across randomized trials of empagliflozin 10 mg daily versus placebo
Effect -0.17 standardised mean difference, 95% CI -0.54 to 0.19
Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.2022PMID:36910362Permalink

Show the remaining 11

pravastatin — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result
“Pravastatin use did not result in a significant change in CRP, LDL particle size, fasting triglycerides, Il-6, or TNF-α (Table 2).”
Quoted verbatim from A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism..
Study

RCT
Duration

3 months
Dose

40 mg/day
Population

Outpatients aged 18 to 68 with schizophrenia or schizoaffective disorder on stable antipsychotic treatment; change from baseline to week 12 in the whole randomised sample
A randomized placebo-controlled pilot study of pravastatin as an adjunctive therapy in schizophrenia patients: effect on inflammation, psychopathology, cognition and lipid metabolism.2014PMID:25261882Permalink
curcumin — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result
“Nanocurcumin supplementation showed no significant effects on fasting blood glucose (SMD: -0.44; 95% CI: -2.16 to 1.28), HbA1c (SMD: 0.19; 95% CI: -1.26 to 1.65), or lipid profile parameters, including total cholesterol, LDL-C, HDL-C and triglycerides (all p > 0.05).”
Quoted verbatim from Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials..
Study

meta-analysis
Participants

373
Population

adults with type 2 diabetes mellitus (T2DM)
Evaluating the Effects of Nanocurcumin Supplementation in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.2026PMID:42171191Permalink
lipoic acid — no detected effect on
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.FindingNull result
“The meta-analysis results indicated that ALA supplementation was not significantly associated with changes in intermediate disease markers, including TG, TC, HDL-C, LDL-C, HOMA-IR or FBS (online supplemental figures S1–S6).”
Quoted verbatim from Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis..
Study

meta-analysis
Dose

300 to 1800 mg/day across trials
Population

Overweight or obese adults (BMI 25 kg/m2 or above) in 11 parallel-design RCTs, some with comorbidities; comparator no intervention or placebo; most trials oral, one intravenous
Alpha-lipoic acid on intermediate disease markers in overweight or obese adults: a systematic review and meta-analysis.2025PMID:40180416Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2
“Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations did not affect following CoQ10 supplementation.”
Quoted verbatim from The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials..
Study

meta-analysis
Population

patients with chronic kidney disease (CKD)
The Effects of Coenzyme Q10 Supplementation on Metabolic Profiles of Patients with Chronic Kidney Disease: A Systematic Review and Meta-analysis of Randomized Controlled Trials.2018PMID:30417782Permalink
magnesium(2+) — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1
“However, our results revealed that Mg supplementation did not have any effect on triglycerides (TG), total cholesterol (TC), and high-density lipoprotein (HDL) serum concentrations among T2DM patients in comparison with the control group.”
Quoted verbatim from The Effects of Magnesium Supplementation on Lipid Profile Among Type 2 Diabetes Patients: a Systematic Review and Meta-analysis of Randomized Controlled Trials..
Study

meta-analysis
Population

Type 2 diabetes mellitus patients
The Effects of Magnesium Supplementation on Lipid Profile Among Type 2 Diabetes Patients: a Systematic Review and Meta-analysis of Randomized Controlled Trials.2021PMID:32468224Permalink
Camellia sinensis — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“The intake of green tea did not significantly influence HDL-cholesterol, triglyceride, and Apo-B levels.”
Quoted verbatim from Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias..
Study

crossover
Duration

8 weeks
Dose

250-mg green tea dry extract capsules
Population

Adults aged 21-71 with dyslipidemias; low-fat background diet; crossover design
Prospective double-blind crossover study of Camellia sinensis (green tea) in dyslipidemias.2009PMID:19838489Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2
“The pooled results indicated that CoQ10 supplementation had no effects on total cholesterol, or LDL-cholesterol, or on HDL-cholesterol, and triglycerides.”
Quoted verbatim from A systematic review for the efficacy of coenzyme Q10 in patients with chronic kidney disease..
Study

meta-analysis
Population

adults with chronic kidney disease (CKD); meta-analysis of 12 studies (17 publications)
A systematic review for the efficacy of coenzyme Q10 in patients with chronic kidney disease.2022PMID:33782820Permalink
resveratrol — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1
“The administration of resveratrol did not affect psychological parameters or blood cholesterol (p=0.091) or triglyceride (p=0.932) levels.”
Quoted verbatim from The Effects of Resveratrol in a Randomized Clinical Trial on Drug-Induced Hyperlipidemia and Psychiatric Factors in People Living with HIV..
Study

RCT
Population

people living with HIV (PLHIV)
The Effects of Resveratrol in a Randomized Clinical Trial on Drug-Induced Hyperlipidemia and Psychiatric Factors in People Living with HIV.2024PMID:39528454Permalink
coenzyme Q10 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×2
“The trial showed no evidence of effect of CoQ10 supplementation on total cholesterol (MD 0.30 mmol/L, 95% CI -0.10 to 0.70), high-density lipoprotein (HDL)-cholesterol (MD 0.02 mmol/L, 95% CI -0.13 to 0.17) or triglycerides (MD 0.05 mmol/L, 95% CI -0.42 to 0.52).”
Quoted verbatim from Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease..
Study

RCT
Population

adults at high risk of cardiovascular disease without a diagnosis of CVD; single RCT (51 patients randomised)
Effect 0.05 mean difference, 95% CI -0.42 to 0.52
Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease.2014PMID:25474484Permalink
magnesium(2+) — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull resultreplicated ×1
“HDL-cholesterol was significantly lower after magnesium compared with placebo (1.14±0.08 vs 1.20±0.09 mmol/l, p=0.026), but no effect on total cholesterol, LDL-cholesterol and triglycerides was found (Table 2).”
Quoted verbatim from Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial..
Study

crossover
Participants

14
Duration

6 weeks
Dose

15 mmol magnesium per day (360 mg) as magnesium gluconate liquid, 50 ml three times daily, for 6 weeks
Population

Adults with insulin-treated type 2 diabetes and serum magnesium at or below 0.79 mmol/l, 14 participants
Oral magnesium supplementation does not affect insulin sensitivity in people with insulin-treated type 2 diabetes and a low serum magnesium: a randomised controlled trial.2024PMID:37922013Permalink
crocin-1 — no detected effect on
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.FindingNull result
“Crocin supplements did not have any significant effect on serum TG (p = 0.144) levels, LDL-C (p = 0.161), and HDL-C (p = 0.872) levels.”
Quoted verbatim from The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials..
Study

meta-analysis
Population

Participants in eight clinical trials of crocin supplementation (nine effect sizes), pooled
The effect of crocin supplementation on lipid concentrations and fasting blood glucose: A systematic review and meta-analysis and meta-regression of randomized controlled trials.2020PMID:32951748Permalink

How it is measured

Serum or plasma triglyceride concentration by clinical enzymatic (glycerol-phosphate-oxidase) assay in a sample drawn after a stated fast. Fast duration is recorded with each finding, because postprandial triglycerides are several-fold higher than fasting values.

Measured, not recorded

Subject: triglycerides
Measurements: 132 measurements
Recorded as a finding: No

Show what was measured

triglycerides
decreases, p = 0.018
Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).
PMID:22930403 · both readings recorded this
triglycerides
decreases, reduction of 65 mg/dL
The triglyceride-lowering effect, a reduction of 65 mg/dL, was also found in this study.
PMID:25131839 · both readings recorded this
triglycerides
decreases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · both readings recorded this
Triglycerides
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
Triglycerides
no effect, n = 103
Intervention with PPE was not associated with significant changes in HDL-cholesterol or triglyceride levels
PMID:22246619 · one of two readings recorded this
Triglycerides
decreases, p = 0.01, n = 46
We found markedly lower levels of TC (p < 0.01), TG (p < 0.01), and LDL (p = 0.02) in the GTE group than in the control group after GTE treatment
PMID:22581111 · one of two readings recorded this
Triglycerides
decreases, p = 0.042, n = 23
GTE treatment caused significant reduction in TC and TG (respectively, p = 0.034 and p = 0.042)
PMID:22581111 · one of two readings recorded this
Triglycerides
no effect, p = 0.06
Triglycerides (mg/dL; 1 mg/dL=0.011 mmol/L) | 185.9 (168.8 to 202.9) | 189.0 (162.6 to 215.4) | 151.8 (133.9 to 169.7) | 135.5 (126.0 to 145.1) | 0.06
PMID:23386268 · one of two readings recorded this
Triglycerides
no effect, p = 0.438
TG (mmol/L) | 2.2 ± 1.6 | 2.0 ± 0.9 | 2.1 ± 1.3 | 2.0 ± 0.7 | 0.509 | 0.229 | 0.438
PMID:23708056 · one of two readings recorded this
triglycerides
decreases
Not recorded as a finding: sentence refers back with 'these results are associated with' rather than independently naming curcumin; not self-supporting as a standalone quote
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
Triglycerides
decreases, p = 0.001, n = 41
Triglycerides, mg/dl | 263±96 | 248±89 | 265±118 | 149±37 *, ° | 0.38 | <0.001
PMID:25148829 · one of two readings recorded this
Triglycerides
no effect
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
Triglycerides
decreases, p = 0.007
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
Triglycerides
no effect, p = 0.05
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
triglycerides
no effect
Triglycerides (TGC, mg/dl) | 214.3 ± 22.4 | 180.4 ± 17.6 | NS | 210.0 ± 28.5 | 198.5 ± 20.4 | NS | 252.8 ± 27.3 | 223.4 ± 25.7 | NS | NS
PMID:26321469 · one of two readings recorded this
Triglycerides
decreases, p = 0.05
TG (mmol/L) | 2.2 ± 1.2 | 1.6 ± 0.9 | P < 0.05 | 2.0 ± 0.8 | 1.9 ± 1.1 | 0.69
PMID:27629750 · one of two readings recorded this
Triglycerides
no effect, p = 0.69
TG (mmol/L) | 2.2 ± 1.2 | 1.6 ± 0.9 | P < 0.05 | 2.0 ± 0.8 | 1.9 ± 1.1 | 0.69
PMID:27629750 · one of two readings recorded this
triglycerides
increases, p = 0.046, n = 936
There was no change in HDL-cholesterol concentration, but triglyceride concentrations increased by 3.6% in the GTE group, whereas they decreased by 2.5% in the placebo group (P = 0.046)
PMID:27806972 · one of two readings recorded this
triglycerides
increases, p = 0.06
The effect of GTE on the increase in triglycerides was mainly observed among obese women and statin users (P-interaction = 0.06)
PMID:27806972 · one of two readings recorded this
Triglycerides
decreases, p = 0.05
triglycerides (-17.7%, p < 0.05)
PMID:28178209 · one of two readings recorded this
Triglycerides
no effect, p = 0.05
No statistically significant (P>0.05) difference in Tg was detected between treatment groups
PMID:28579756 · one of two readings recorded this
triglycerides
decreases
significant reductions of triglycerides of 0.368 mmol L-1 [95% confidence interval (CI) = -0.427 to -0.309]
PMID:28675488 · one of two readings recorded this
triglycerides
modulates
The triglyceride-lowering effect was dose-dependent
PMID:28675488 · one of two readings recorded this
triglycerides
no effect
No changes were observed between treatment arms in HDL-C, triglycerides, fasting plasma glucose (FPG), glycated haemoglobin (HbA1C), waist circumference and body mass index (BMI) levels
PMID:28704936 · one of two readings recorded this
triglycerides
no effect, n = 118
Serum TG and LDL-C changes did not show any significant difference between the study groups (p>0.05).
PMID:28735818 · one of two readings recorded this
triglycerides
no effect
Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations did not affect following CoQ10 supplementation
PMID:30417782 · one of two readings recorded this
Triglycerides
decreases, p = 0.002
triglycerides (TG) (MD = -0.28 mmol/l 95% CI [-0.46, -0.10], p = 0.002)
PMID:30466986 · one of two readings recorded this
triglycerides
n = 15
Triglycerides (mg/dL) | 67.0 ± 17.1 | 77.6 ± 26.0 | 62.5 ± 12.3 | < 150
PMID:30904021 · one of two readings recorded this
Triglycerides
decreases, p = 0.04
A meta-analysis of 13 trials which reported the data on triglyceride (TG) revealed a borderline significant effect of the L-Arginine on TG values (WMD = -6.03 mg/dl; 95% CI: -12, -0.07, P = 0.04)
PMID:31442577 · one of two readings recorded this
triglycerides
Tg (mg/dl) | 124.2±25.8 | 130.8±28.3 | 135.1±31.2 | 128.3±27.5 | 133.4±28.9 | 134.7±29.2
PMID:31695332 · one of two readings recorded this
triglycerides
no effect
Tg (mg/dl) | 124.2±25.8 | 130.8±28.3 | 135.1±31.2 | 128.3±27.5 | 133.4±28.9 | 134.7±29.2
PMID:31695332 · one of two readings recorded this
triglycerides
Tg (mg/dl) | 124.2±25.8 | 130.8±28.3 | 135.1±31.2 | 128.3±27.5 | 133.4±28.9 | 134.7±29.2
PMID:31695332 · one of two readings recorded this
triglycerides
decreases
a greater reduction in triglycerides (TG) (WMD -0.191 mmol l-1; 95% CI -0.249, -0.133)
PMID:32175534 · one of two readings recorded this
triglycerides
decreases
the WMD for TG was much lower in trials with participants >40 years old (-0.246 mmol l-1; 95% CI -0.325, -0.167)
PMID:32175534 · one of two readings recorded this
triglycerides
no effect
there were no significant differences between lycopene intervention and control groups for blood pressure and lipids (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides)
PMID:32652029 · one of two readings recorded this
triglycerides
decreases
In contrast, high-dose supplementation only showed significant effects for TGs
PMID:32722790 · one of two readings recorded this
triglycerides
decreases
Short-duration supplementation benefited only TGs, while long-duration supplementation was beneficial for TGs, TC, and LDL cholesterol
PMID:32722790 · one of two readings recorded this
triglycerides
decreases
The effect of dose on the CVD risk factors was similar, with low-dose zinc supplementation showing significant, beneficial effects for TGs, TC, and LDL cholesterol
PMID:32722790 · one of two readings recorded this
triglycerides
decreases
Short-duration supplementation benefited only TGs, while long-duration supplementation was beneficial for TGs, TC, and LDL cholesterol
PMID:32722790 · one of two readings recorded this
Triglycerides
no effect
Similarly, FBS, TG, and HDLc with L-carnitine intervention presented no significant difference between the intervention and control groups
PMID:32932644 · one of two readings recorded this
Triglycerides
decreases
The levels of FBS and TG in the high-dose groups were significantly decreased (FBS, −11.41 mg/dL, −16.10 to −6.72 mg/dL; TG, −29.85 mg/dL, −60.08 to 0.38 mg/dL)
PMID:32932644 · one of two readings recorded this
Triglycerides
no effect
Non-significant results were found for the levels of FBS, TG, and HDLc in the low-dose groups
PMID:32932644 · one of two readings recorded this
Triglycerides
In patients treated with curcumin, a non-significant reduction in plasma triglyceride concentrations, without statistical heterogeneity, was identified (Table 2,.
PMID:33514002 · one of two readings recorded this
triglycerides
decreases
TG (WMD = -0.77 mmol/L; 95% CI, -1.54, -0.00 mmol/L)
PMID:34229258 · one of two readings recorded this
triglycerides
increases
an increase in the TG level (151.84 ± 15.46 mg/dL vs. 176.52 ± 14.5 mg/dL)
PMID:34444811 · one of two readings recorded this
triglycerides
decreases, p = 0.001
164.2 ± 32.3 mg/dL vs. 129.2 ± 34.1 mg/dL, p < 0.001
PMID:34444811 · one of two readings recorded this
triglycerides
decreases
Summarized findings suggest that curcumin supplementation can significantly reduce blood glucose and triglycerides levels, including markers of liver function like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with T2D and NAFLD.
PMID:34847213 · one of two readings recorded this
triglycerides
no effect
No significant reductions in the biochemical parameters of TG, HDL, HbA1c, body weight, or, therefore, BMI following curcumin supplementation were observed
PMID:34959992 · one of two readings recorded this
triglycerides
no effect, p = 0.8
no differences were detected between groups for HDL cholesterol (P = 0.4) and triglycerides (P = 0.8)
PMID:35575618 · one of two readings recorded this
Triglycerides
decreases, p = 0.001
Triglycerides (mmol/L), median (IQR) | 0.7 (0.5–1.1) | 1.1 (0.8–1.6) | <.001
PMID:35585781 · one of two readings recorded this
Triglycerides
no effect
MD, −0.40 mmol/L; CI: −0.89 to 0.09
PMID:36008064 · one of two readings recorded this
Triglycerides
no effect
MD, −0.23 mmol/L; CI: −0.50 to 0.04
PMID:36008064 · one of two readings recorded this
Triglycerides
decreases
MD, −1.10 mmol/L; 95% CI: −1.90 to –0.30
PMID:36008064 · one of two readings recorded this
Triglycerides
no effect
MD, 0.30 mmol/L; 95% CI: −0.46 to 1.06
PMID:36008064 · one of two readings recorded this
Triglycerides
no effect
MD, −0.80 mmol/L; 95% CI: −1.64 to 0.04
PMID:36008064 · one of two readings recorded this
Triglycerides
decreases, p = 0.05
significant decrease in FBG, insulin, HbA1c, HOMO-IR, LDL-c, TG, VLDL, CHOL, LDL-c.HDL-c ratio, AIP, IL-6, and MDA and a significant increase in HDL-c, QUICKI index, BDNF, and TAC compared with the initial value (p for all <.05)
PMID:36101997 · one of two readings recorded this
Triglycerides
no effect, p = 0.28
TG (mg/dL) | 156.4 ± 77.9 | 123.1 ± 48.4 | − 33.3 ± 14.0 | 0.02 | 158.0 ± 65.3 | 135.7 ± 51.7 | − 22.3 ± 8.9 | 0.01 | 0.28
PMID:36307427 · one of two readings recorded this
triglycerides
Not recorded as a finding: One-sided negation ('does not significantly improve') does not establish no_effect (rule 1a).
This meta-analysis showed that selenium supplementation has a positive effect on TAC, and supplementation of selenium does not significantly improve the level of BMI, Weight, LDL, HDL, Triglycerides, Total Testosterone, HOMA-IR, NO, GSH, MDA and FPG.
PMID:36740666 · one of two readings recorded this
Triglycerides
no effect
supplementation of selenium does not significantly improve the level of BMI, Weight, LDL, HDL, Triglycerides, Total Testosterone, HOMA-IR, NO, GSH, MDA and FPG
PMID:36740666 · one of two readings recorded this
triglycerides
no effect, p = 0.44
triglyceride (TG) (SMD, -0.14; 95% CI, -0.49 to 0.21; p = 0.44; I2 = 76%)
PMID:36805484 · one of two readings recorded this
triglycerides
decreases
Berberine plus statins significantly reduced TC, TG, LDL-C, NIHSS score, hs-CRP, TNF-α, IMT, Crouse score, and number of unstable plaques levels than routine or statins
PMID:36805484 · one of two readings recorded this
Triglycerides
decreases, n = 1661
triglycerides (- 0.34 mmol/L, 95% CI - 0.46 to - 0.23, 18 studies, n = 1661)
PMID:36941490 · one of two readings recorded this
triglycerides
decreases
TG effects were similar (MD -17.40 mg/dL [95%CI: -32.57 to -2.23])
PMID:37183391 · one of two readings recorded this
triglycerides
decreases
TG (MD -18.67 mg/dL [95%CI: -25.82 to -11.51])
PMID:37183391 · one of two readings recorded this
triglycerides
increases, p = 0.04
Group 3 subjects had a significant (p = 0.04) increase in their triglyceride values (from 123.80 ± 53.69 before intervention to 151.20 ± 41.47) after intervention
PMID:37229639 · one of two readings recorded this
triglycerides
decreases, mean -4.25%; 95% CI of mean -11.11 to 2.61, high-dose group only
Regarding TG concentrations, we observed a slight but significant reduction with treatment-only in the high-dose-treated group (mean −4.25%; 95% CI of mean −11.11 to 2.61).
PMID:37375586 · one of two readings recorded this
triglycerides
decreases, p = 0.01
triglycerides (TG) (2.2 ± 0.7 vs. 2.1 ± 0.7 mmol/L, P < .01)
PMID:37405785 · one of two readings recorded this
triglycerides
decreases
hypoxic inducible factor-1 α (HIF-1α), cysteine protease-3 (Caspase-3), the national institutes of health stroke scale (NIHSS), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C)
PMID:37421347 · one of two readings recorded this
triglycerides
decreases
Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%, total cholesterol by 16.1% to 23.3%,and triglycerides by 5.8% to 20.0%
PMID:37721222 · one of two readings recorded this
Triglycerides
no effect, p = 0.261, n = 14
Triglycerides, mmol/l | 2.3±0.5 | 1.8±0.3 | 0.261
PMID:37922013 · one of two readings recorded this
triglycerides
decreases, p = 0.05
The results showed total cholesterol and triglycerides and low-density lipoprotein of participants of treatment group 3 who received both MO and AS were statistically significant (p<0.05)
PMID:38008957 · one of two readings recorded this
triglycerides
no effect, p = 0.41
Triglycerides, mg/dL b | 94.6 ± 46.4 | 90.1 ± 39.6 | 0.41
PMID:38110301 · one of two readings recorded this
Triglycerides
decreases, p = 0.005, n = 68
After 12 weeks | 157.39 ± 41.29 | 214.23 ± 98.10 | 0.005
PMID:38200253 · one of two readings recorded this
Triglycerides
no effect, p = 0.551, n = 68
TG (mg/dL) | Baseline | 234.24 ± 96.94 | 255.67 ± 175.03 | 0.551
PMID:38200253 · one of two readings recorded this
Triglycerides
decreases, p = 0.001, n = 34
Pb | < 0.001 | < 0.001
PMID:38200253 · one of two readings recorded this
Triglycerides
decreases, p = 0.001, n = 34
Pb | < 0.001 | < 0.001
PMID:38200253 · one of two readings recorded this
triglycerides
no effect, SMD=-0.60, 95% CI -1.25 to 0.04, p = 0.06
Pooled analysis of triglyceride (TG) (mmol/L) showed no difference between GKB and control (SMD=-0.60, 95%CI [-1.25, 0.04], P=0.06).
PMID:38264278 · one of two readings recorded this
triglycerides
no effect
TG (WMD: 6⋅02 mg/dl, 95 % CI: −2⋅58, 14⋅62, P = 0⋅170)
PMID:38282652 · one of two readings recorded this
triglycerides
no effect, p = 0.05
TG (MD = 0.06; 95% CI: 0.00, 0.12; peffect = 0.05)
PMID:38542695 · one of two readings recorded this
Triglycerides
increases, p = 0.05
but TC (p = 0.01) and TG (p = 0.05) slightly increased in individuals receiving 500 mg/day of resveratrol
PMID:38790615 · one of two readings recorded this
Triglycerides
no effect, p = 0.827, n = 15
(mg/dL) | AX | 15 | 117.7 ± 40.9 | 132.5 ± 45.0† | 125.1 ± 14.7 | G x T | 0.827 | 0.002
PMID:39568140 · one of two readings recorded this
Triglycerides
increases, n = 15
Triglycerides | PLA | 15 | 130.9 ± 70.0 | 144.7 ± 67.2† | 137.8 ± 14.7 | T | 0.000 | 0.558
PMID:39568140 · one of two readings recorded this
Triglycerides
no effect, p = 0.36, n = 567
TG | 8 | 567 | (−0.15, 0.26) | 0.81 | 0.00% (0.00% to 0.56%) | 0 | −0.078 (−0.24 to 0.09) | 0.36
PMID:40180416 · one of two readings recorded this
Triglycerides
no effect
Besides, ALA administered alone does not significantly impact TG levels
PMID:40180416 · one of two readings recorded this
Triglycerides
decreases
However, when ALA is combined with other components, it demonstrates a small yet significant positive effect on reducing TG levels (online supplemental figure S30)
PMID:40180416 · one of two readings recorded this
Triglycerides
decreases, 47.25±2.22
Notably, cholesterol (49.00±6.48), triglycerides (47.25±2.22), LDL (34.50±3.11), uric acid (4.90±0.22), urea (46.00±0.82), creatinine (0.35±0.03), blood glucose (193.00±11.20), and weight gain (77.75±2.06) were lower.
PMID:40292062 · one of two readings recorded this
triglycerides
decreases
Notably, cholesterol (49.00±6.48), triglycerides (47.25±2.22), LDL (34.50±3.11), uric acid (4.90±0.22), urea (46.00±0.82), creatinine (0.35±0.03), blood glucose (193.00±11.20), and weight gain (77.75±2.06) were lower
PMID:40292062 · one of two readings recorded this
triglycerides
unclear, p = 0.012
triglycerides (p = 0.012, ηp2 = 0.042), and the cholesterol/HDL ratio (p = 0.009, ηp2 = 0.044)
PMID:40573153 · one of two readings recorded this
triglycerides
no effect, WMD 0.00, 95% CI -0.14 to 0.14, p = 1
The analysis indicated no clinical or statistical effect of Mg supplementation on TG levels (WMD = 0.00, 95% CI: –0.14 to 0.14; P = 1.00).
PMID:40641714 · one of two readings recorded this
triglycerides
decreases, p = 0.002
triglycerides (TG) by 17.8% (P = 0.002)
PMID:40770379 · one of two readings recorded this
triglycerides
no effect, p = 0.16
Figure 7 shows that that there was no significant difference between the selenium and placebo groups on the TG levels of the patients (P = 0.16, MD = −16.80, 95% CI: −40.29, 6.70)
PMID:41073938 · one of two readings recorded this
triglycerides
increases, n = 80
0.023% (95% CI: 0.011-0.036) higher triglycerides
PMID:41162813 · one of two readings recorded this
triglycerides
decreases
Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol
PMID:41184790 · one of two readings recorded this
Triglycerides
decreases, p = 0.021
Post-hoc test showed significantly lower in CT + P (d: 2.76, p < 0.001), CT (d: 2.75, p < 0.001), S (d: 1.36, p = 0.021), and CT + S (d: 2.95, p < 0.001) compared with P group.
PMID:41249265 · one of two readings recorded this
Triglycerides
p = 0.001
triglycerides (TG) (F(5,83) = 23.29, p < 0.001, η2 = 0.591)
PMID:41249265 · one of two readings recorded this
Triglycerides
decreases, p = 0.003
Also, the Post-hoc test showed significantly lower in CT + S compared with S (d: 1.59, p = 0.003).
PMID:41249265 · one of two readings recorded this
triglycerides
no effect, WMD -9.28 mg/dL, 95% CI -20.76 to 2.20
However, no significant overall change was observed in HDL (WMD: 1.71 mg/dL; 95% CI − 0.63 to 4.04; I2 = 99.95%) and TG (WMD: − 9.28 mg/dL; 95% CI − 20.76 to 2.20; I2 = 100%).
PMID:41555409 · one of two readings recorded this
triglycerides
decreases
triglycerides (WMD: -13.73 mg/dL; 95% CI: -19.49, -7.96)
PMID:41656101 · one of two readings recorded this
Triglycerides
no effect
TG (WMD: -17.27, 95% CI: -46.85 to 12.31)
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Age | ≥ 50 years | 2 | -4.03 (-17.66 to 9.60) | 30.6 | 0.230
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
BMI | ≥ 30 kg/m2 | 3 | -8.25 (-36.86 to 20.36) | 34.9 | 0.215
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Dose | 1200 mg | 2 | 1.97 (-46.82 to 50.76) | 55.8 | 0.133
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
≤ 400 mg | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
≤ 12 weeks | 2 | 1.97 (-46.82 to 50.76) | 55.8 | 0.133
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Follow-up | ≥ 24 weeks | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
FibroScan | 1 | -20.00 (-50.88 to 10.88) | - | -
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Liver biopsy | 1 | -1.00 (-3.96 to 1.96) | - | -
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Diagnosis of NAFLD | Ultrasonography | 3 | -21.59 (-73.79 to 30.60) | 82.8 | 0.003
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Sample size | ≥ 50 participants | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
increases, p = 0.05
the Lp05 group had significantly higher triglyceride levels at baseline compared to the placebo group (P < 0.05), but this difference was no longer present at S2
PMID:42117710 · one of two readings recorded this
Triglycerides
no effect
Throughout the 24-week intervention, lipid profiles, including total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol, remained stable and within normal reference ranges in both the placebo and probiotic groups, with no statistically significant differences observed between groups
PMID:42124006 · one of two readings recorded this
triglycerides
no effect, SMD 0.05, 95% CI -0.53 to 0.64, not significant, p = 0.86, n = 373
Results showed that consuming nanocurcumin did not significantly reduce triglyceride levels [SMD: 0.05, 95% CI: (−0.53, 0.64), p = 0.86]
PMID:42171191 · one of two readings recorded this
triglycerides
no effect, p = 0.86
Results showed that consuming nanocurcumin did not significantly reduce triglyceride levels [SMD: 0.05, 95% CI: (−0.53, 0.64), p = 0.86].
PMID:42171191 · one of two readings recorded this
Triglycerides
no effect, p = 0.87
from 90.83 ± 49.07 to 81.75 ± 27.49, 10% reduction from baseline to the wash-out period, p = 0.87
PMID:42197276 · one of two readings recorded this
Triglycerides
no effect, p = 0.2
Triglyceride concentrations decreased in the active group at week 5 (from 90.83 ± 49.07 to 85.75 ± 41.24, 5.6% reduction from the baseline to week 5, p = 0.2)
PMID:42197276 · one of two readings recorded this
Triglycerides
no effect, p = 0.6
at week 9 (from 90.83 ± 49.07 to 81.55 ± 35.08, 10.2% reduction from the baseline to week 9, p = 0.6)
PMID:42197276 · one of two readings recorded this
triglycerides
decreases
lipids (triglycerides to 0.72 mmol/L), liver enzymes (ALT to 9.74 U/L), and UACR (to 7.36 mg/g)
PMID:42199793 · one of two readings recorded this
Triglycerides
Baseline | 141.92 ± 55.54 | 161.97 ± 114.20
PMID:42303733 · one of two readings recorded this
Triglycerides
decreases, p = 0.272
Mean changes | − 17.34 ± 9.34 | − 21.02 ± 16.64 | 0.435 | 0.272
PMID:42303733 · one of two readings recorded this
Triglycerides
decreases, p = 0.435
Mean changes | − 17.34 ± 9.34 | − 21.02 ± 16.64 | 0.435 | 0.272
PMID:42303733 · one of two readings recorded this
Triglycerides
decreases, p = 0.071
Pa | 0.071 | 0.214
PMID:42303733 · one of two readings recorded this
Triglycerides
decreases, p = 0.214
Pa | 0.071 | 0.214
PMID:42303733 · one of two readings recorded this
triglycerides
decreases, p = 0.001, n = 51
Triglycerides (mmol/L) | 51 | 1.74 (0.84) | 1.36 (0.72) | −0.38 [−0.57 to −0.19] | < 0.001
PMID:42420793 · one of two readings recorded this
Triglycerides
increases, p = 0.05, n = 39
Triglycerides were higher after sucrose than saccharin (p < 0.05), while no differences were seen for cholesterol, apolipoproteins, or CRP
PMID:42514406 · one of two readings recorded this
Triglycerides
decreases, p = 0.008
while triglycerides serum level was significantly decreased within the control group (p = 0.008)
PMID:42587287 · one of two readings recorded this
triglycerides
decreases, WMD -9.24 mg/dL, 95% CI -16.87 to -1.61
The meta-analysis revealed that Mg supplementation considerably decreased TG (WMD: −9.24 mg/dL, 95% CI: −16.87 to −1.61) and LDL-C levels (WMD: −3.21 mg/dL, 95% CI: −5.27, −1.15) in comparison with the placebo group.
PMID:42588058 · one of two readings recorded this
triglycerides
no effect, p = 0.66
No significant differences were observed (MD = −5.37; 95% CI −29.55 to 18.81; p = 0.66)
PMID:42594341 · one of two readings recorded this
Triglycerides
no effect, p = 0.858
TG | 0.0099 [-0.0990 – 0.1188] | 0.858 | -0.0171 [-0.0768 – 0.0427] | 0.576
PMID:42802824 · one of two readings recorded this
Triglycerides
no effect, p = 0.816
Triglycerides (mmol/L) | 1.58 (1.16) | 1.55 (0.92) | 0.816
PMID:42802824 · one of two readings recorded this

Sources cited

41 papers

Subject: triglycerides
Findings: 41
Papers: 41

Compound

Direction

Findings

Strongest evidence

no effect 2 · down 2

down

down 2 · no effect 1

no effect

down 1 · no effect 1

down 1 · no effect 1

no effect

Lactiplantibacillus plantarum

no effect

down

no effect

down

down

down

down

no effect 1 · down 4

no effect

no effect

all-cis-docosa-4,7,10,13,16,19-hexaenoic acid

down

no effect

down

down

down

down

Measured, not recorded

Subject

triglycerides

Measurements

132 measurements

Recorded as a finding

Show what was measured

triglycerides
decreases, p = 0.018
Curcuminoids also led to a significant decrease in serum total FFAs (p < 0.01), triglycerides (P = 0.018), an increase in LPL activity (p < 0.01).
PMID:22930403 · both readings recorded this
triglycerides
decreases, reduction of 65 mg/dL
The triglyceride-lowering effect, a reduction of 65 mg/dL, was also found in this study.
PMID:25131839 · both readings recorded this
triglycerides
decreases, n = 100
Curcuminoids were more effective than placebo in reducing serum LDL-C, non-HDL-C, total cholesterol, triglycerides and Lp(a), and elevating HDL-C concentrations.
PMID:25440375 · both readings recorded this
Triglycerides
no effect
Green tea beverage or green tea extract supplementation did not significantly affect features of metabolic syndrome as defined in this study, including waist circumference, systolic and diastolic blood pressure, triglycerides, HDL, and fasting glucose versus no treatment group
PMID:20605696 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
triglycerides
decreases
Both EPA and DHA reduced triglycerides, with a greater reduction by DHA in direct comparison studies
PMID:21975919 · one of two readings recorded this
Triglycerides
no effect, n = 103
Intervention with PPE was not associated with significant changes in HDL-cholesterol or triglyceride levels
PMID:22246619 · one of two readings recorded this
Triglycerides
decreases, p = 0.01, n = 46
We found markedly lower levels of TC (p < 0.01), TG (p < 0.01), and LDL (p = 0.02) in the GTE group than in the control group after GTE treatment
PMID:22581111 · one of two readings recorded this
Triglycerides
decreases, p = 0.042, n = 23
GTE treatment caused significant reduction in TC and TG (respectively, p = 0.034 and p = 0.042)
PMID:22581111 · one of two readings recorded this
Triglycerides
no effect, p = 0.06
Triglycerides (mg/dL; 1 mg/dL=0.011 mmol/L) | 185.9 (168.8 to 202.9) | 189.0 (162.6 to 215.4) | 151.8 (133.9 to 169.7) | 135.5 (126.0 to 145.1) | 0.06
PMID:23386268 · one of two readings recorded this
Triglycerides
no effect, p = 0.438
TG (mmol/L) | 2.2 ± 1.6 | 2.0 ± 0.9 | 2.1 ± 1.3 | 2.0 ± 0.7 | 0.509 | 0.229 | 0.438
PMID:23708056 · one of two readings recorded this
triglycerides
decreases
Not recorded as a finding: sentence refers back with 'these results are associated with' rather than independently naming curcumin; not self-supporting as a standalone quote
These results are associated with reduced levels of homeostasis model assessment-insulin resistance, triglyceride, uric acid, visceral fat and total body fat.
PMID:24445038 · one of two readings recorded this
Triglycerides
decreases, p = 0.001, n = 41
Triglycerides, mg/dl | 263±96 | 248±89 | 265±118 | 149±37 *, ° | 0.38 | <0.001
PMID:25148829 · one of two readings recorded this
Triglycerides
no effect
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
Triglycerides
decreases, p = 0.007
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
Triglycerides
no effect, p = 0.05
TG(mmol/L) | -0.02(-0.24~0.21) | -0.12(-0.36~0.12) | -0.45(-0.68~-0.23) | 0.007 | 0.050
PMID:26252777 · one of two readings recorded this
triglycerides
no effect
Triglycerides (TGC, mg/dl) | 214.3 ± 22.4 | 180.4 ± 17.6 | NS | 210.0 ± 28.5 | 198.5 ± 20.4 | NS | 252.8 ± 27.3 | 223.4 ± 25.7 | NS | NS
PMID:26321469 · one of two readings recorded this
Triglycerides
decreases, p = 0.05
TG (mmol/L) | 2.2 ± 1.2 | 1.6 ± 0.9 | P < 0.05 | 2.0 ± 0.8 | 1.9 ± 1.1 | 0.69
PMID:27629750 · one of two readings recorded this
Triglycerides
no effect, p = 0.69
TG (mmol/L) | 2.2 ± 1.2 | 1.6 ± 0.9 | P < 0.05 | 2.0 ± 0.8 | 1.9 ± 1.1 | 0.69
PMID:27629750 · one of two readings recorded this
triglycerides
increases, p = 0.046, n = 936
There was no change in HDL-cholesterol concentration, but triglyceride concentrations increased by 3.6% in the GTE group, whereas they decreased by 2.5% in the placebo group (P = 0.046)
PMID:27806972 · one of two readings recorded this
triglycerides
increases, p = 0.06
The effect of GTE on the increase in triglycerides was mainly observed among obese women and statin users (P-interaction = 0.06)
PMID:27806972 · one of two readings recorded this
Triglycerides
decreases, p = 0.05
triglycerides (-17.7%, p < 0.05)
PMID:28178209 · one of two readings recorded this
Triglycerides
no effect, p = 0.05
No statistically significant (P>0.05) difference in Tg was detected between treatment groups
PMID:28579756 · one of two readings recorded this
triglycerides
decreases
significant reductions of triglycerides of 0.368 mmol L-1 [95% confidence interval (CI) = -0.427 to -0.309]
PMID:28675488 · one of two readings recorded this
triglycerides
modulates
The triglyceride-lowering effect was dose-dependent
PMID:28675488 · one of two readings recorded this
triglycerides
no effect
No changes were observed between treatment arms in HDL-C, triglycerides, fasting plasma glucose (FPG), glycated haemoglobin (HbA1C), waist circumference and body mass index (BMI) levels
PMID:28704936 · one of two readings recorded this
triglycerides
no effect, n = 118
Serum TG and LDL-C changes did not show any significant difference between the study groups (p>0.05).
PMID:28735818 · one of two readings recorded this
triglycerides
no effect
Triglycerides, HDL-cholesterol, fasting glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), and C-reactive protein (CRP) concentrations did not affect following CoQ10 supplementation
PMID:30417782 · one of two readings recorded this
Triglycerides
decreases, p = 0.002
triglycerides (TG) (MD = -0.28 mmol/l 95% CI [-0.46, -0.10], p = 0.002)
PMID:30466986 · one of two readings recorded this
triglycerides
n = 15
Triglycerides (mg/dL) | 67.0 ± 17.1 | 77.6 ± 26.0 | 62.5 ± 12.3 | < 150
PMID:30904021 · one of two readings recorded this
Triglycerides
decreases, p = 0.04
A meta-analysis of 13 trials which reported the data on triglyceride (TG) revealed a borderline significant effect of the L-Arginine on TG values (WMD = -6.03 mg/dl; 95% CI: -12, -0.07, P = 0.04)
PMID:31442577 · one of two readings recorded this
triglycerides
Tg (mg/dl) | 124.2±25.8 | 130.8±28.3 | 135.1±31.2 | 128.3±27.5 | 133.4±28.9 | 134.7±29.2
PMID:31695332 · one of two readings recorded this
triglycerides
no effect
Tg (mg/dl) | 124.2±25.8 | 130.8±28.3 | 135.1±31.2 | 128.3±27.5 | 133.4±28.9 | 134.7±29.2
PMID:31695332 · one of two readings recorded this
triglycerides
Tg (mg/dl) | 124.2±25.8 | 130.8±28.3 | 135.1±31.2 | 128.3±27.5 | 133.4±28.9 | 134.7±29.2
PMID:31695332 · one of two readings recorded this
triglycerides
decreases
a greater reduction in triglycerides (TG) (WMD -0.191 mmol l-1; 95% CI -0.249, -0.133)
PMID:32175534 · one of two readings recorded this
triglycerides
decreases
the WMD for TG was much lower in trials with participants >40 years old (-0.246 mmol l-1; 95% CI -0.325, -0.167)
PMID:32175534 · one of two readings recorded this
triglycerides
no effect
there were no significant differences between lycopene intervention and control groups for blood pressure and lipids (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides)
PMID:32652029 · one of two readings recorded this
triglycerides
decreases
In contrast, high-dose supplementation only showed significant effects for TGs
PMID:32722790 · one of two readings recorded this
triglycerides
decreases
Short-duration supplementation benefited only TGs, while long-duration supplementation was beneficial for TGs, TC, and LDL cholesterol
PMID:32722790 · one of two readings recorded this
triglycerides
decreases
The effect of dose on the CVD risk factors was similar, with low-dose zinc supplementation showing significant, beneficial effects for TGs, TC, and LDL cholesterol
PMID:32722790 · one of two readings recorded this
triglycerides
decreases
Short-duration supplementation benefited only TGs, while long-duration supplementation was beneficial for TGs, TC, and LDL cholesterol
PMID:32722790 · one of two readings recorded this
Triglycerides
no effect
Similarly, FBS, TG, and HDLc with L-carnitine intervention presented no significant difference between the intervention and control groups
PMID:32932644 · one of two readings recorded this
Triglycerides
decreases
The levels of FBS and TG in the high-dose groups were significantly decreased (FBS, −11.41 mg/dL, −16.10 to −6.72 mg/dL; TG, −29.85 mg/dL, −60.08 to 0.38 mg/dL)
PMID:32932644 · one of two readings recorded this
Triglycerides
no effect
Non-significant results were found for the levels of FBS, TG, and HDLc in the low-dose groups
PMID:32932644 · one of two readings recorded this
Triglycerides
In patients treated with curcumin, a non-significant reduction in plasma triglyceride concentrations, without statistical heterogeneity, was identified (Table 2,.
PMID:33514002 · one of two readings recorded this
triglycerides
decreases
TG (WMD = -0.77 mmol/L; 95% CI, -1.54, -0.00 mmol/L)
PMID:34229258 · one of two readings recorded this
triglycerides
increases
an increase in the TG level (151.84 ± 15.46 mg/dL vs. 176.52 ± 14.5 mg/dL)
PMID:34444811 · one of two readings recorded this
triglycerides
decreases, p = 0.001
164.2 ± 32.3 mg/dL vs. 129.2 ± 34.1 mg/dL, p < 0.001
PMID:34444811 · one of two readings recorded this
triglycerides
decreases
Summarized findings suggest that curcumin supplementation can significantly reduce blood glucose and triglycerides levels, including markers of liver function like alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with T2D and NAFLD.
PMID:34847213 · one of two readings recorded this
triglycerides
no effect
No significant reductions in the biochemical parameters of TG, HDL, HbA1c, body weight, or, therefore, BMI following curcumin supplementation were observed
PMID:34959992 · one of two readings recorded this
triglycerides
no effect, p = 0.8
no differences were detected between groups for HDL cholesterol (P = 0.4) and triglycerides (P = 0.8)
PMID:35575618 · one of two readings recorded this
Triglycerides
decreases, p = 0.001
Triglycerides (mmol/L), median (IQR) | 0.7 (0.5–1.1) | 1.1 (0.8–1.6) | <.001
PMID:35585781 · one of two readings recorded this
Triglycerides
no effect
MD, −0.40 mmol/L; CI: −0.89 to 0.09
PMID:36008064 · one of two readings recorded this
Triglycerides
no effect
MD, −0.23 mmol/L; CI: −0.50 to 0.04
PMID:36008064 · one of two readings recorded this
Triglycerides
decreases
MD, −1.10 mmol/L; 95% CI: −1.90 to –0.30
PMID:36008064 · one of two readings recorded this
Triglycerides
no effect
MD, 0.30 mmol/L; 95% CI: −0.46 to 1.06
PMID:36008064 · one of two readings recorded this
Triglycerides
no effect
MD, −0.80 mmol/L; 95% CI: −1.64 to 0.04
PMID:36008064 · one of two readings recorded this
Triglycerides
decreases, p = 0.05
significant decrease in FBG, insulin, HbA1c, HOMO-IR, LDL-c, TG, VLDL, CHOL, LDL-c.HDL-c ratio, AIP, IL-6, and MDA and a significant increase in HDL-c, QUICKI index, BDNF, and TAC compared with the initial value (p for all <.05)
PMID:36101997 · one of two readings recorded this
Triglycerides
no effect, p = 0.28
TG (mg/dL) | 156.4 ± 77.9 | 123.1 ± 48.4 | − 33.3 ± 14.0 | 0.02 | 158.0 ± 65.3 | 135.7 ± 51.7 | − 22.3 ± 8.9 | 0.01 | 0.28
PMID:36307427 · one of two readings recorded this
triglycerides
Not recorded as a finding: One-sided negation ('does not significantly improve') does not establish no_effect (rule 1a).
This meta-analysis showed that selenium supplementation has a positive effect on TAC, and supplementation of selenium does not significantly improve the level of BMI, Weight, LDL, HDL, Triglycerides, Total Testosterone, HOMA-IR, NO, GSH, MDA and FPG.
PMID:36740666 · one of two readings recorded this
Triglycerides
no effect
supplementation of selenium does not significantly improve the level of BMI, Weight, LDL, HDL, Triglycerides, Total Testosterone, HOMA-IR, NO, GSH, MDA and FPG
PMID:36740666 · one of two readings recorded this
triglycerides
no effect, p = 0.44
triglyceride (TG) (SMD, -0.14; 95% CI, -0.49 to 0.21; p = 0.44; I2 = 76%)
PMID:36805484 · one of two readings recorded this
triglycerides
decreases
Berberine plus statins significantly reduced TC, TG, LDL-C, NIHSS score, hs-CRP, TNF-α, IMT, Crouse score, and number of unstable plaques levels than routine or statins
PMID:36805484 · one of two readings recorded this
Triglycerides
decreases, n = 1661
triglycerides (- 0.34 mmol/L, 95% CI - 0.46 to - 0.23, 18 studies, n = 1661)
PMID:36941490 · one of two readings recorded this
triglycerides
decreases
TG effects were similar (MD -17.40 mg/dL [95%CI: -32.57 to -2.23])
PMID:37183391 · one of two readings recorded this
triglycerides
decreases
TG (MD -18.67 mg/dL [95%CI: -25.82 to -11.51])
PMID:37183391 · one of two readings recorded this
triglycerides
increases, p = 0.04
Group 3 subjects had a significant (p = 0.04) increase in their triglyceride values (from 123.80 ± 53.69 before intervention to 151.20 ± 41.47) after intervention
PMID:37229639 · one of two readings recorded this
triglycerides
decreases, mean -4.25%; 95% CI of mean -11.11 to 2.61, high-dose group only
Regarding TG concentrations, we observed a slight but significant reduction with treatment-only in the high-dose-treated group (mean −4.25%; 95% CI of mean −11.11 to 2.61).
PMID:37375586 · one of two readings recorded this
triglycerides
decreases, p = 0.01
triglycerides (TG) (2.2 ± 0.7 vs. 2.1 ± 0.7 mmol/L, P < .01)
PMID:37405785 · one of two readings recorded this
triglycerides
decreases
hypoxic inducible factor-1 α (HIF-1α), cysteine protease-3 (Caspase-3), the national institutes of health stroke scale (NIHSS), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C)
PMID:37421347 · one of two readings recorded this
triglycerides
decreases
Pravastatin 10 mg/day to 80 mg/day reduced LDL cholesterol by 21.7% to 31.9%, total cholesterol by 16.1% to 23.3%,and triglycerides by 5.8% to 20.0%
PMID:37721222 · one of two readings recorded this
Triglycerides
no effect, p = 0.261, n = 14
Triglycerides, mmol/l | 2.3±0.5 | 1.8±0.3 | 0.261
PMID:37922013 · one of two readings recorded this
triglycerides
decreases, p = 0.05
The results showed total cholesterol and triglycerides and low-density lipoprotein of participants of treatment group 3 who received both MO and AS were statistically significant (p<0.05)
PMID:38008957 · one of two readings recorded this
triglycerides
no effect, p = 0.41
Triglycerides, mg/dL b | 94.6 ± 46.4 | 90.1 ± 39.6 | 0.41
PMID:38110301 · one of two readings recorded this
Triglycerides
decreases, p = 0.005, n = 68
After 12 weeks | 157.39 ± 41.29 | 214.23 ± 98.10 | 0.005
PMID:38200253 · one of two readings recorded this
Triglycerides
no effect, p = 0.551, n = 68
TG (mg/dL) | Baseline | 234.24 ± 96.94 | 255.67 ± 175.03 | 0.551
PMID:38200253 · one of two readings recorded this
Triglycerides
decreases, p = 0.001, n = 34
Pb | < 0.001 | < 0.001
PMID:38200253 · one of two readings recorded this
Triglycerides
decreases, p = 0.001, n = 34
Pb | < 0.001 | < 0.001
PMID:38200253 · one of two readings recorded this
triglycerides
no effect, SMD=-0.60, 95% CI -1.25 to 0.04, p = 0.06
Pooled analysis of triglyceride (TG) (mmol/L) showed no difference between GKB and control (SMD=-0.60, 95%CI [-1.25, 0.04], P=0.06).
PMID:38264278 · one of two readings recorded this
triglycerides
no effect
TG (WMD: 6⋅02 mg/dl, 95 % CI: −2⋅58, 14⋅62, P = 0⋅170)
PMID:38282652 · one of two readings recorded this
triglycerides
no effect, p = 0.05
TG (MD = 0.06; 95% CI: 0.00, 0.12; peffect = 0.05)
PMID:38542695 · one of two readings recorded this
Triglycerides
increases, p = 0.05
but TC (p = 0.01) and TG (p = 0.05) slightly increased in individuals receiving 500 mg/day of resveratrol
PMID:38790615 · one of two readings recorded this
Triglycerides
no effect, p = 0.827, n = 15
(mg/dL) | AX | 15 | 117.7 ± 40.9 | 132.5 ± 45.0† | 125.1 ± 14.7 | G x T | 0.827 | 0.002
PMID:39568140 · one of two readings recorded this
Triglycerides
increases, n = 15
Triglycerides | PLA | 15 | 130.9 ± 70.0 | 144.7 ± 67.2† | 137.8 ± 14.7 | T | 0.000 | 0.558
PMID:39568140 · one of two readings recorded this
Triglycerides
no effect, p = 0.36, n = 567
TG | 8 | 567 | (−0.15, 0.26) | 0.81 | 0.00% (0.00% to 0.56%) | 0 | −0.078 (−0.24 to 0.09) | 0.36
PMID:40180416 · one of two readings recorded this
Triglycerides
no effect
Besides, ALA administered alone does not significantly impact TG levels
PMID:40180416 · one of two readings recorded this
Triglycerides
decreases
However, when ALA is combined with other components, it demonstrates a small yet significant positive effect on reducing TG levels (online supplemental figure S30)
PMID:40180416 · one of two readings recorded this
Triglycerides
decreases, 47.25±2.22
Notably, cholesterol (49.00±6.48), triglycerides (47.25±2.22), LDL (34.50±3.11), uric acid (4.90±0.22), urea (46.00±0.82), creatinine (0.35±0.03), blood glucose (193.00±11.20), and weight gain (77.75±2.06) were lower.
PMID:40292062 · one of two readings recorded this
triglycerides
decreases
Notably, cholesterol (49.00±6.48), triglycerides (47.25±2.22), LDL (34.50±3.11), uric acid (4.90±0.22), urea (46.00±0.82), creatinine (0.35±0.03), blood glucose (193.00±11.20), and weight gain (77.75±2.06) were lower
PMID:40292062 · one of two readings recorded this
triglycerides
unclear, p = 0.012
triglycerides (p = 0.012, ηp2 = 0.042), and the cholesterol/HDL ratio (p = 0.009, ηp2 = 0.044)
PMID:40573153 · one of two readings recorded this
triglycerides
no effect, WMD 0.00, 95% CI -0.14 to 0.14, p = 1
The analysis indicated no clinical or statistical effect of Mg supplementation on TG levels (WMD = 0.00, 95% CI: –0.14 to 0.14; P = 1.00).
PMID:40641714 · one of two readings recorded this
triglycerides
decreases, p = 0.002
triglycerides (TG) by 17.8% (P = 0.002)
PMID:40770379 · one of two readings recorded this
triglycerides
no effect, p = 0.16
Figure 7 shows that that there was no significant difference between the selenium and placebo groups on the TG levels of the patients (P = 0.16, MD = −16.80, 95% CI: −40.29, 6.70)
PMID:41073938 · one of two readings recorded this
triglycerides
increases, n = 80
0.023% (95% CI: 0.011-0.036) higher triglycerides
PMID:41162813 · one of two readings recorded this
triglycerides
decreases
Sulforaphane led to significant reductions in metabolic markers, including LDL, triglycerides, and cholesterol
PMID:41184790 · one of two readings recorded this
Triglycerides
decreases, p = 0.021
Post-hoc test showed significantly lower in CT + P (d: 2.76, p < 0.001), CT (d: 2.75, p < 0.001), S (d: 1.36, p = 0.021), and CT + S (d: 2.95, p < 0.001) compared with P group.
PMID:41249265 · one of two readings recorded this
Triglycerides
p = 0.001
triglycerides (TG) (F(5,83) = 23.29, p < 0.001, η2 = 0.591)
PMID:41249265 · one of two readings recorded this
Triglycerides
decreases, p = 0.003
Also, the Post-hoc test showed significantly lower in CT + S compared with S (d: 1.59, p = 0.003).
PMID:41249265 · one of two readings recorded this
triglycerides
no effect, WMD -9.28 mg/dL, 95% CI -20.76 to 2.20
However, no significant overall change was observed in HDL (WMD: 1.71 mg/dL; 95% CI − 0.63 to 4.04; I2 = 99.95%) and TG (WMD: − 9.28 mg/dL; 95% CI − 20.76 to 2.20; I2 = 100%).
PMID:41555409 · one of two readings recorded this
triglycerides
decreases
triglycerides (WMD: -13.73 mg/dL; 95% CI: -19.49, -7.96)
PMID:41656101 · one of two readings recorded this
Triglycerides
no effect
TG (WMD: -17.27, 95% CI: -46.85 to 12.31)
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Age | ≥ 50 years | 2 | -4.03 (-17.66 to 9.60) | 30.6 | 0.230
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
BMI | ≥ 30 kg/m2 | 3 | -8.25 (-36.86 to 20.36) | 34.9 | 0.215
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Dose | 1200 mg | 2 | 1.97 (-46.82 to 50.76) | 55.8 | 0.133
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
≤ 400 mg | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
≤ 12 weeks | 2 | 1.97 (-46.82 to 50.76) | 55.8 | 0.133
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Follow-up | ≥ 24 weeks | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
FibroScan | 1 | -20.00 (-50.88 to 10.88) | - | -
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Liver biopsy | 1 | -1.00 (-3.96 to 1.96) | - | -
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Diagnosis of NAFLD | Ultrasonography | 3 | -21.59 (-73.79 to 30.60) | 82.8 | 0.003
PMID:41917882 · one of two readings recorded this
Triglycerides
no effect
Sample size | ≥ 50 participants | 3 | -26.56 (-66.86 to 13.74) | 92.9 | < 0.001
PMID:41917882 · one of two readings recorded this
Triglycerides
increases, p = 0.05
the Lp05 group had significantly higher triglyceride levels at baseline compared to the placebo group (P < 0.05), but this difference was no longer present at S2
PMID:42117710 · one of two readings recorded this
Triglycerides
no effect
Throughout the 24-week intervention, lipid profiles, including total cholesterol, triglycerides, HDL-cholesterol, and LDL-cholesterol, remained stable and within normal reference ranges in both the placebo and probiotic groups, with no statistically significant differences observed between groups
PMID:42124006 · one of two readings recorded this
triglycerides
no effect, SMD 0.05, 95% CI -0.53 to 0.64, not significant, p = 0.86, n = 373
Results showed that consuming nanocurcumin did not significantly reduce triglyceride levels [SMD: 0.05, 95% CI: (−0.53, 0.64), p = 0.86]
PMID:42171191 · one of two readings recorded this
triglycerides
no effect, p = 0.86
Results showed that consuming nanocurcumin did not significantly reduce triglyceride levels [SMD: 0.05, 95% CI: (−0.53, 0.64), p = 0.86].
PMID:42171191 · one of two readings recorded this
Triglycerides
no effect, p = 0.87
from 90.83 ± 49.07 to 81.75 ± 27.49, 10% reduction from baseline to the wash-out period, p = 0.87
PMID:42197276 · one of two readings recorded this
Triglycerides
no effect, p = 0.2
Triglyceride concentrations decreased in the active group at week 5 (from 90.83 ± 49.07 to 85.75 ± 41.24, 5.6% reduction from the baseline to week 5, p = 0.2)
PMID:42197276 · one of two readings recorded this
Triglycerides
no effect, p = 0.6
at week 9 (from 90.83 ± 49.07 to 81.55 ± 35.08, 10.2% reduction from the baseline to week 9, p = 0.6)
PMID:42197276 · one of two readings recorded this
triglycerides
decreases
lipids (triglycerides to 0.72 mmol/L), liver enzymes (ALT to 9.74 U/L), and UACR (to 7.36 mg/g)
PMID:42199793 · one of two readings recorded this
Triglycerides
Baseline | 141.92 ± 55.54 | 161.97 ± 114.20
PMID:42303733 · one of two readings recorded this
Triglycerides
decreases, p = 0.272
Mean changes | − 17.34 ± 9.34 | − 21.02 ± 16.64 | 0.435 | 0.272
PMID:42303733 · one of two readings recorded this
Triglycerides
decreases, p = 0.435
Mean changes | − 17.34 ± 9.34 | − 21.02 ± 16.64 | 0.435 | 0.272
PMID:42303733 · one of two readings recorded this
Triglycerides
decreases, p = 0.071
Pa | 0.071 | 0.214
PMID:42303733 · one of two readings recorded this
Triglycerides
decreases, p = 0.214
Pa | 0.071 | 0.214
PMID:42303733 · one of two readings recorded this
triglycerides
decreases, p = 0.001, n = 51
Triglycerides (mmol/L) | 51 | 1.74 (0.84) | 1.36 (0.72) | −0.38 [−0.57 to −0.19] | < 0.001
PMID:42420793 · one of two readings recorded this
Triglycerides
increases, p = 0.05, n = 39
Triglycerides were higher after sucrose than saccharin (p < 0.05), while no differences were seen for cholesterol, apolipoproteins, or CRP
PMID:42514406 · one of two readings recorded this
Triglycerides
decreases, p = 0.008
while triglycerides serum level was significantly decreased within the control group (p = 0.008)
PMID:42587287 · one of two readings recorded this
triglycerides
decreases, WMD -9.24 mg/dL, 95% CI -16.87 to -1.61
The meta-analysis revealed that Mg supplementation considerably decreased TG (WMD: −9.24 mg/dL, 95% CI: −16.87 to −1.61) and LDL-C levels (WMD: −3.21 mg/dL, 95% CI: −5.27, −1.15) in comparison with the placebo group.
PMID:42588058 · one of two readings recorded this
triglycerides
no effect, p = 0.66
No significant differences were observed (MD = −5.37; 95% CI −29.55 to 18.81; p = 0.66)
PMID:42594341 · one of two readings recorded this
Triglycerides
no effect, p = 0.858
TG | 0.0099 [-0.0990 – 0.1188] | 0.858 | -0.0171 [-0.0768 – 0.0427] | 0.576
PMID:42802824 · one of two readings recorded this
Triglycerides
no effect, p = 0.816
Triglycerides (mmol/L) | 1.58 (1.16) | 1.55 (0.92) | 0.816
PMID:42802824 · one of two readings recorded this